Just weeks after FibroGen, Inc.'s lead asset roxadustat failed to win approval from the US Food and Drug Administration for anemia in chronic kidney disease, the company announced positive clinical trial data for the drug in a different indication, chemotherapy-induced anemia. The results of the Phase II WHITNEY trial released on 25 August could provide an opportunity for FibroGen to pivot to the chemotherapy-induced anemia indication in the US.
FibroGen May Have A New Opening For Roxadustat In The US
The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.

More from Blood and Clotting
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.